Journal Of Cancer Research And Clinical Oncology SCIE

国际简称：J CANCER RES CLIN 参考译名：癌症研究与临床肿瘤学杂志

主要研究方向：医学-肿瘤学非预警期刊审稿周期：约1.0个月

《癌症研究与临床肿瘤学杂志》(Journal Of Cancer Research And Clinical Oncology)是一本由Springer Berlin Heidelberg出版的以医学-肿瘤学为研究特色的国际期刊，发表该领域相关的原创研究文章、评论文章和综述文章，及时报道该领域相关理论、实践和应用学科的最新发现，旨在促进该学科领域科学信息的快速交流。该期刊是一本未开放期刊，近三年没有被列入预警名单。

3区中科院分区
Q3 JCR分区
969 年发文量
2.7 IF影响因子
未开放 是否OA
87 H-index
1904 创刊年份
Monthly 出版周期
English 出版语言

The "Journal of Cancer Research and Clinical Oncology" publishes significant and up-to-date articles within the fields of experimental and clinical oncology. The journal, which is chiefly devoted to Original papers, also includes Reviews as well as Editorials and Guest editorials on current, controversial topics. The section Letters to the editors provides a forum for a rapid exchange of comments and information concerning previously published papers and topics of current interest. Meeting reports provide current information on the latest results presented at important congresses.

The following fields are covered: carcinogenesis - etiology, mechanisms; molecular biology; recent developments in tumor therapy; general diagnosis; laboratory diagnosis; diagnostic and experimental pathology; oncologic surgery; and epidemiology.

[ 查看全部 ]

投稿咨询加急咨询

投稿热线：400-888-7501

Journal Of Cancer Research And Clinical Oncology期刊信息

ISSN：0171-5216
出版语言：English
是否OA：未开放
E-ISSN：1432-1335
出版地区：GERMANY
是否预警：否
出版商：Springer Berlin Heidelberg
出版周期：Monthly
创刊时间：1904
开源占比：0.366
Gold OA文章占比：35.02%
OA被引用占比：0.1835...
出版国人文章占比：0.24
出版撤稿占比：0
研究类文章占比：89.06%

Journal Of Cancer Research And Clinical Oncology CiteScore评价数据（2024年最新版）

CiteScore

SJR

SNIP

CiteScore 指数

1.023

0.953

学科类别	分区	排名	百分位
大类：Medicine 小类：Oncology	Q3	207 / 404	48%
大类：Medicine 小类：Cancer Research	Q3	154 / 230	33%

名词解释：CiteScore 是衡量期刊所发表文献的平均受引用次数，是在 Scopus 中衡量期刊影响力的另一个指标。当年CiteScore 的计算依据是期刊最近4年（含计算年度）的被引次数除以该期刊近四年发表的文献数。例如，2022年的 CiteScore 计算方法为：2022年的 CiteScore =2019-2022年收到的对2019-2022年发表的文件的引用数量÷2019-2022年发布的文献数量注：文献类型包括：文章、评论、会议论文、书籍章节和数据论文。

Journal Of Cancer Research And Clinical Oncology中科院评价数据

中科院 2023年12月升级版

Top期刊	综述期刊	大类学科		小类学科
否	否	医学	3区	ONCOLOGY 肿瘤学	4区

中科院 2022年12月升级版

Top期刊	综述期刊	大类学科		小类学科
否	否	医学	3区	ONCOLOGY 肿瘤学	3区

中科院 2021年12月旧的升级版

Top期刊	综述期刊	大类学科		小类学科
否	否	医学	3区	ONCOLOGY 肿瘤学	3区

中科院 2021年12月基础版

Top期刊	综述期刊	大类学科		小类学科
否	否	医学	3区	ONCOLOGY 肿瘤学	3区

中科院 2021年12月升级版

Top期刊	综述期刊	大类学科		小类学科
否	否	医学	3区	ONCOLOGY 肿瘤学	3区

中科院 2020年12月旧的升级版

Top期刊	综述期刊	大类学科		小类学科
否	否	医学	2区	ONCOLOGY 肿瘤学	3区

Journal Of Cancer Research And Clinical Oncology JCR评价数据（2023-2024年最新版）

按JIF指标学科分区	收录子集	分区	排名	百分位
学科：ONCOLOGY	SCIE	Q3	163 / 322	49.5%

按JCI指标学科分区	收录子集	分区	排名	百分位
学科：ONCOLOGY	SCIE	Q3	172 / 322	46.74%

Journal Of Cancer Research And Clinical Oncology历年数据统计

影响因子

中科院分区

Journal Of Cancer Research And Clinical Oncology中国学者发文选摘

1、Sintilimab with chemotherapy as first-line treatment for locally advanced or metastatic squamous non-small-cell lung cancer: a real-world data study
Author: Lin, Xinqing; Deng, Haiyi; Li, Suyang; Xie, Xiaohong; Chen, Chao; Cai, Longqiu; Yang, Yilin; Qiu, Guihuan; Xie, Zhanhong; Qin, Yinyin; Liu, Ming; Zhou, Chengzhi

Journal: JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY. 2023; Vol. 149, Issue 2, pp. 757-764. DOI: 10.1007/s00432-021-03903-0
2、Surufatinib plus toripalimab in patients with advanced solid tumors: a single-arm, open-label, phase 1 trial
Author: Cao, Yanshuo; Lu, Ming; Sun, Yu; Gong, Jifang; Li, Jie; Lu, Zhihao; Li, Jian; Zhang, Xiaotian; Li, Yan; Peng, Zhi; Zhou, Jun; Wang, Xicheng; Shen, Lin

Journal: JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY. 2023; Vol. 149, Issue 2, pp. 779-789. DOI: 10.1007/s00432-021-03898-8
3、Interim analysis of the efficiency and safety of neoadjuvant PD-1 inhibitor (sintilimab) combined with chemotherapy (nab-paclitaxel and carboplatin) in potentially resectable stage IIIA/IIIB non-small cell lung cancer: a single-arm, phase 2 trial
Author: Sun, Chao; Liu, Yunpeng; Zhang, Peng; Wang, Xu; Xu, Yinghui; Lin, Xingyu; Ma, Xiaobo; Guo, Ye; Qiu, Shi; Shao, Guoguang; Yang, Zhiguang; Ma, Kewei

Journal: JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY. 2023; Vol. 149, Issue 2, pp. 819-831. DOI: 10.1007/s00432-021-03896-w
4、Analysis of online plan adaptation for 1.5T magnetic resonance-guided stereotactic body radiotherapy (MRgSBRT) of prostate cancer
Author: Poon, Darren M. C.; Yang, Bin; Geng, Hui; Wong, Oi Lei; Chiu, Sin Ting; Cheung, Kin Yin; Yu, Siu Ki; Chiu, George; Yuan, Jing

Journal: JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY. 2023; Vol. 149, Issue 2, pp. 841-850. DOI: 10.1007/s00432-022-03950-1
5、Comparison of clinical characteristics, treatment efficacy and survival in patients with newly diagnosed multiple myeloma with single- versus multi-site extramedullary invasion
Author: Zhao, Yongfeng; Zhou, Fuling

Journal: JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY. 2023; Vol. 149, Issue 3, pp. 995-1006. DOI: 10.1007/s00432-022-03948-9
6、The genomic characteristics of RET fusion positive tumors in Chinese non-small cell lung cancer (NSCLC) patients
Author: Wu, Guowu; Guo, Longhua; Gu, Yinfang; Huang, Tanxiao; Liu, Ming; Zou, Xiaofang; Yang, Bo; Huang, Ping; Wen, Chunling; Yi, Lilan; Liao, Wenting; Zhao, Dongdong; Zhu, Junlin; Zhang, Xiaoni; Liu, Yuanyuan; Yin, Yan; Chen, Shifu

Journal: JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY. 2023; Vol. 149, Issue 3, pp. 1019-1028. DOI: 10.1007/s00432-022-03959-6
7、Pulmonary neuroendocrine tumors: study of 266 cases focusing on clinicopathological characteristics, immunophenotype, and prognosis
Author: Zhang, Shuwen; Chen, Jingjing; Zhang, Rui; Xu, Liqin; Wang, Yan; Yuan, Zaixin; Hou, Xiaohui; Feng, Jian

Journal: JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY. 2023; Vol. 149, Issue 3, pp. 1063-1077. DOI: 10.1007/s00432-022-03970-x
8、Optimizing the tumor shrinkage threshold for evaluating immunotherapy efficacy for advanced non-small-cell lung cancer
Author: Du, Wei; Chen, Chen; Lin-feng Luo; Li-na He; Wang, Yixing; Zhang, Xuanye; Zhou, Yixin; Lin, Zuan; Hong, Shaodong

Journal: JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY. 2023; Vol. 149, Issue 3, pp. 1103-1113. DOI: 10.1007/s00432-022-03978-3